

5. Rootman J, Tisdall J, Gudauskas G, Ostry A. Intraocular penetration of subconjunctivally administered 14 C-fluorouracil in rabbits. *Arch Ophthalmol* 1979;97:2375–8.
6. Kondo M, Araie M. Concentration change of fluorouracil in the external segment of the eye after subconjunctival injection. *Arch Ophthalmol* 1988;106:1718–21.
7. Ball SF. Concentration change and activity of fluorouracil in the external segment of the eye after subconjunctival injection. *Arch Ophthalmol* 1989;107:1276–7.
8. Khaw PT, Ward S, Porter A, Grierson I, Hitchings RA, Rice NSC. The long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts. *Invest Ophthalmol Vis Sci* 1992;33:2043–52.
9. Khaw PT, Sherwood MB, MacKay SLD, Rossi MJ, Schultz GS. Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. *Arch Ophthalmol* 1992;110:1150–4.
10. Khaw PT, Doyle JW, Sherwood MB, Grierson I, McGorray S, Schultz GS. Five-minute exposures to 5-fluorouracil and mitomycin-c have prolonged localised tissue effects. *Arch Ophthalmol* 1993 (in press).
11. Loftfield K, Ball SF. 5-Fluorouracil (5-FU) in primary trabeculectomy: a randomised trial. *Invest Ophthalmol Vis Sci (Suppl)* 1991;32:745.
12. Khaw PT, Doyle JW, Sherwood MB, Smith MF, McGorray S. Effects of intraoperative 5-fluorouracil or mitomycin-c on glaucoma filtration surgery in the rabbit. *Ophthalmology* 1993 (in press).
13. Kitazawa Y, Kawase K, Matsushita H, Minobe M. Trabeculectomy with mitomycin: a comparative study with fluorouracil. *Arch Ophthalmol* 1991;109:1693–8.
14. Skuta GL, Beeson CC, Higginbotham EJ, Lichter PR, Musch DC, Bergstrom TJ, *et al.* Intraoperative mitomycin versus postoperative 5-fluorouracil in high-risk glaucoma filtering surgery. *Ophthalmology* 1992;99:438–44.
15. Lanigan LP, Stuermer J, Hitchings RA, Khaw PT. Single intraoperative exposures to 5-fluorouracil: early results. *Ophthalmology* 1993 (in press).

Sir,

Hulbert and Vernon<sup>1</sup> have performed a valuable service in reminding ophthalmologists who treat diabetic retinopathy of the importance of preserving as much of the visual field as possible. However, I suspect that they may be advocating dangerous undertreatment of patients with proliferative diabetic retinopathy.

Most authors recognise that 'complete treatment' of proliferative retinopathy by panretinal photocoagulation requires approximately 1800–2000 laser burns of 500  $\mu\text{m}$  size. This was the basis of laser treatment applied in the Diabetic Retinopathy Study<sup>2</sup> and forms the guidelines for present-day management of proliferative diabetic retinopathy.<sup>3</sup> Patients with aggressive retinopathy may well, of course, require much more laser treatment.

Hulbert and Vernon advocate the use of 200  $\mu\text{m}$  spot size laser burns and comment in their guidelines that 'between 3000 and 3500 carefully applied burns induces regression in all but severe cases'. Using a 200  $\mu\text{m}$  spot size it would require 12 500 laser burns to cover the same area of retina as the 'conventional' 2000 burns of spot size 500  $\mu\text{m}$ . They therefore appear to be advocating consider-

ably less laser treatment than is currently the norm, and I suspect this could well be a dangerous undertreatment. Furthermore, as far as I am aware, this form of treatment has never been tested in controlled studies and as such should, in my opinion, be regarded with caution.

J. M. Gibson, MD, FRCS, FROphth  
East Birmingham Hospital, NHS Trust  
Bordesley Green East  
Birmingham B9 5ST, UK

### References

1. Hulbert MFL, Vernon SA. Passing the DVLC field regulations following bilateral pan-retinal photo-coagulation in diabetics. *Eye* 1992;6:456–60.
2. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative retinopathy: clinical applications of Diabetic Retinopathy Study (DRS) findings. DRS Report no. 8. *Ophthalmology* 1981;88:583–600.
3. Bloom SM, Brucker AJ. Laser surgery of the posterior segment. Philadelphia: Lippincott, 1991:25–51.

Sir,

I am grateful to Mr. Gibson for re-emphasising the importance of delivering sufficient laser photocoagulation to induce neovascular regression in proliferative diabetic retinopathy. I had hoped that this would be covered by Guideline 5 in our paper.<sup>1</sup> We are, of course, aware that our suggestions (specifically designed for individuals who require a driving licence) result in a smaller area of retina being photocoagulated. Our experience, as outlined in the tables,<sup>1</sup> would indicate that, based on the degree of severity of retinopathy of patients referred to our clinic, many do not require our 'standard retinal ablation' to induce stability of their disease. Titrating treatment in these patients, provided there are adequate facilities for follow-up, would not appear to prejudice the end result; thus a decision to deliver 2000 burns at 500  $\mu\text{m}$  spot size in a patient who does not need that volume of photocoagulation is clearly unjustified. Conversely, patients with rapidly progressive, aggressive retinopathy (which would fall into the severe category) must be treated with more extensive photo-ablation.

Stephen A. Vernon, FRCS, FCOphth  
University Hospital  
Queen's Medical Centre  
Nottingham NG7 2UH, UK

### References

1. Hulbert MFL, Vernon SA. Passing the DVLC field regulations following bilateral pan-retinal photo-coagulation in diabetics. *Eye* 1992;6:456–60.